Statement on New ASH Clinical Practice Guidelines on Sickle Cell Disease-Related Transfusion Support
Published on: January 27, 2020
(WASHINGTON, Jan. 27, 2020) – Today, the American
Society of Hematology (ASH) released new clinical practice guidelines on Sickle
Cell Disease (SCD)-Related Transfusion Support. These guidelines are part of a
series of five guidelines ASH is developing on SCD to provide updated treatment
guidelines that reflect the newest evidence about the disease, ensuring the
medical community can better treat SCD and people with SCD can make the best
decisions for their care.
published in the Society’s peer-reviewed journal Blood Advances. Three
more chapters are in development. ASH previously published SCD-Related
Cardiopulmonary and Kidney Disease Guidelines in December 2019.
“It is an incredibly exciting time with nearly
limitless potential for helping treat people living with SCD. But, we know that
people living with SCD often require blood transfusions to prevent or treat
organ damage associated with the disease. The ASH guidelines took the latest
evidence into account to make recommendations that will help physicians and
caregivers standardize and advance their patients’ care and decrease side
effects. We’ve also provided best-practices and tips for patients and
caregivers to help inform conversations with their health care providers,” said
Stella T. Chou, MD, Co-Chair, ASH Guidelines on SCD-Related Transfusion
Support, and associate professor of pediatrics at the Children’s Hospital of
Philadelphia. “ASH believes it is essential to provide updated treatment
guidelines that reflect this increased knowledge and can help the medical
community better treat SCD.”
Sickle Cell Disease (SCD) is a rare inherited blood
disorder that affects red blood cells and occurs when a person has inherited a
sickle cell gene from each parent. It is estimated to affect approximately
100,000 people in the U.S., and one out of every 365 African-American births.
In 2016, ASH initiated an effort to develop clinical
practice guidelines on SCD. ASH appointed 61 clinical experts, five
methodologists and 10 patient representatives to review evidence and form
recommendations on SCD. The recommendations address treatment of both adult and
pediatric SCD. The systematic review of evidence was led by the Mayo Clinic
Evidence-Based Practice Center.
To learn more about the specific guidelines
recommendations (12 total), and find additional resources, visit www.hematology.org/SCDGuidelines.
The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest
professional society of hematologists dedicated to furthering the
understanding, diagnosis, treatment, and prevention of disorders affecting the
blood. For more than 60 years, the Society has led the development of
hematology as a discipline by promoting research, patient care, education,
training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in
the field, and Blood Advances (www.bloodadvances.org), an online,
peer-reviewed open-access journal.
back to top
Fischer, firstname.lastname@example.org, 202-823-4884